FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine and deals with composition, which contains non-covalent complex of pig alpha-fetoprotein (PAFP), obtained from blood and amniotic liquid of pig embryos by butanol extraction, and at least one agent, which induces apoptosis. Invention also relates to application of claimed composition for inhibition of proliferation of patient's cancer cell, which has alpha-fetoprotein receptor on its surface; application of claimed composition for treatment of multiple drug resistance of refractory malignant neoplasms in patient.
EFFECT: invention ensures reliable and cheap source of product.
25 cl, 8 ex, 7 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| IAP INHIBITORS | 2013 |
|
RU2728789C2 |
| IAP INHIBITORS | 2013 |
|
RU2593259C2 |
| METHODS OF TREATING CANCER, HAVING HEMIZYGOUS LOSS OF TP53 | 2016 |
|
RU2721953C2 |
| COMPOSITION AND METHOD OF TUMOUR CURING | 2007 |
|
RU2500815C2 |
| METHOD FOR PREDICTION OF METASTASES DEVELOPMENT IN PATIENTS WITH GASTRIC CANCER | 2016 |
|
RU2624505C1 |
| APOPTOSIS DETECTION TECHNIQUES AND REAGENTS | 2007 |
|
RU2450273C2 |
| INHIBITION OF NF-κB BY TRITERPENE COMPOSITIONS | 2001 |
|
RU2288706C2 |
| INDUCTION OF APOPTOSIS IN TUMOUR CELLS, EXPRESSING TOLL-LIKE RECEPTOR | 2005 |
|
RU2401661C9 |
| USE OF GENETICALLY MODIFIED PATHOGENIC MEASLES VIRUS WITH IMPROVED APOPTOTIC PROPERTIES (MV-DELTAC VIRUS) IN CANCER THERAPY | 2014 |
|
RU2700083C2 |
| ANALYSES AND METHODS OF BIOMARKER APPLICATION | 2006 |
|
RU2409817C2 |
